A Phase Ib Study of Selinexor in Combination with Pembrolizumab in Patients with Metastatic Melanoma.
Saved in:
| Title: | A Phase Ib Study of Selinexor in Combination with Pembrolizumab in Patients with Metastatic Melanoma. |
|---|---|
| Authors: | Gouda MA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Stephen B; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tian Y; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Alshawa A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Onwugaje DOC; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Albittar A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yang Y; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zarifa A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yilmaz B; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gurses S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Sprenger A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Derbala MH; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Brink A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., How JA; Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Moyers J; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA, USA., Piha-Paul SA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hong DS; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Patel SP; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Oliva IG; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. |
| Source: | Journal of immunotherapy and precision oncology [J Immunother Precis Oncol] 2024 Nov 01; Vol. 7 (4), pp. 247-254. Date of Electronic Publication: 2024 Nov 01 (Print Publication: 2024). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Innovative Healthcare Institute Country of Publication: United States NLM ID: 101768397 Publication Model: eCollection Cited Medium: Internet ISSN: 2590-017X (Electronic) Linking ISSN: 2590017X NLM ISO Abbreviation: J Immunother Precis Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
